

Depressive recurrence on antidepressant treatment (DRAT): 4 next-step options

Boadie W. Dunlop, MD

Dr. Dunlop is Assistant Professor, Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA.

Disclosure

Dr. Dunlop receives grant or research support from Bristol-Myers Squibb, Forest Pharmaceuticals, and GlaxoSmithKline, and is a consultant to MedAvante and Roche.

“**P**oop-out” and “tachyphylaxis” are terms used to describe loss of antidepressant response after initial benefit, but both descriptors are problematic. Poop-out carries a mildly offensive aura that conveys a lack of seriousness about the patient’s suffering. Tachyphylaxis is a pharmacologic term describing rapid or acute reduction in response to a drug after administration; it is not appropriate for antidepressant loss of response, which typically occurs months to years after treatment initiation.¹

Depressive recurrence on antidepressant treatment (DRAT) is a better term to describe recurrence of a major depressive episode despite sustained treatment with an antidepressant that had induced remission. Maintenance studies of antidepressant treatment indicate DRAT occurs in approximately 10% of patients at 6 months and 20% at 2 years.²

Despite this high prevalence, there is little clinical trial data on which to base treatment decisions for patients who experience DRAT. There are 4 options:

1. Raise the dose. In small studies, doubling the dose of fluoxetine or duloxetine led to regaining response in approximately 60% of patients.³ However, these studies lacked a placebo comparison arm, so the specific benefit derived from the dose increase is un-

known. Improvement with a dose increase is somewhat at odds with the known mechanism of action of selective serotonin reuptake inhibitors (SSRIs), which are thought to have a flat dose-response curve. That is, once an SSRI blocks approximately 80% of the serotonin transporters, further dose increases produce minimal further blockade and, presumably, little clinical benefit via this mechanism.⁴

2. Switch medication. No studies have examined switching antidepressants after DRAT. Switching to a medication with a different mechanism may be justified based on the results of treatment-resistant depression (TRD) trials, in which patients who failed to respond to an initial medication—typically an SSRI—improved after switching to an antidepressant from a different class. However, the biology of DRAT may differ from that of SSRI nonresponse. Unlike many patients with TRD, patients who experience DRAT while taking an SSRI have demonstrated previous response to serotonergic modulation.

3. Augmentation. Similar to switching, this approach has not been studied specifically for DRAT. This approach is derived from trials in which patients who did not attain response after treatment with a single antidepressant had a second medication added. Again, the biology of these patients may differ from those with DRAT, who at one point did remit with antidepressant treatment.

4. Psychotherapy. This addition is a low-risk option for patients who previously have not received evidence-based psychotherapy for depression.



Discuss this article at www.facebook.com/CurrentPsychiatry

PSYCHIATRY **Find it**

For more information, go to CurrentPsychiatry.com

Personalizing depression treatment

© Current Psychiatry

Clinicians have scant evidence on which to base their decisions for this common and important problem. Dose increase after DRAT represents the best supported, simplest, and perhaps least costly next step in treatment.

References

1. Rothschild AJ, Dunlop BW, Dunner DL, et al. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER

for two years (PREVENT) study. *Psychopharmacol Bull.* 2009;42(3):5-20.

2. Hansen R, Gaynes B, Thieda P, et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. *Psychiatr Serv.* 2008;59(10):1121-1130.
3. Schmidt ME, Fava M, Zhang S, et al. Treatment approaches to major depressive disorder relapse. Part 1: dose increase. *Psychother Psychosom.* 2002;71(4):190-194.
4. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. *Am J Psychiatry.* 2004;161(5):826-835.

In DRAT patients, consider raising the antidepressant dose, switching or augmenting medication, or psychotherapy

Want to better understand challenges and opportunities in schizophrenia treatment?

Don't miss this new supplement to CURRENT PSYCHIATRY!

This supplement reviews the safety and efficacy challenges that clinicians and their adult patients with schizophrenia face when considering treatment options. The supplement also presents data from clinical trials of Latuda® (lurasidone HCl), an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia.



INDICATIONS AND USAGE

LATUDA is an atypical antipsychotic indicated for the treatment of patients with schizophrenia. Efficacy was established in five 6-week controlled studies of adult patients with schizophrenia. The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

IMPORTANT SAFETY INFORMATION FOR LATUDA

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
- LATUDA is not approved for the treatment of patients with dementia-related psychosis.

Please see additional Important Safety Information, including **Boxed Warning**, and Brief Summary of Prescribing Information on adjacent pages.

This supplement is sponsored by



is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U. S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. ©2013 Sunovion Pharmaceuticals Inc. All rights reserved. 2/13 LAT021-13



View this important update today at CurrentPsychiatry.com. Click on [Supplements](#).